Cel­gene's AML drug clears late-stage test

Cel­gene is gear­ing up for reg­u­la­to­ry sub­mis­sions af­ter a piv­otal acute myeloid leukemia (AML) study showed its drug helped pa­tients live longer.

The drug­mak­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER